Prenuvo and UT Dallas researchers found links between sleep efficiency, visceral fat and brain volume, with long sleepers ...

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.

Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.

The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary care from 2027.

Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.

United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD.

A Biograph study using AI on routine heart CT scans found inflammation that cholesterol tests and risk calculators could not ...

XellSmart’s off-the-shelf XS411 lifted motor scores in nine patients, and its 30-person Phase II trial has finished enrolling ...

As pharma shops for de-risked science, venture money is moving later and concentrating in fewer, bigger bets – our report ...

German biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein.

TimePie's Hebe Chen spotlights key developments from Shanghai, from therapeutic targets to China’s expanding clinical ...